These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33578296)

  • 1. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients: a Retrospective Analysis.
    Stein BD; Smart R; Jones CM; Sheng F; Powell D; Sorbero M
    J Gen Intern Med; 2021 Oct; 36(10):2952-2957. PubMed ID: 33598891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
    Saloner B; Levin J; Chang HY; Jones C; Alexander GC
    JAMA Netw Open; 2018 Aug; 1(4):e181588. PubMed ID: 30646116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Intern Med; 2024 Aug; 184(8):954-962. PubMed ID: 38884975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
    Mark TL; Parish WJ; Zarkin GA
    JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose.
    Follman S; Arora VM; Lyttle C; Moore PQ; Pho MT
    JAMA Netw Open; 2019 May; 2(5):e193209. PubMed ID: 31050777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients.
    Chang HY; Krawczyk N; Schneider KE; Ferris L; Eisenberg M; Richards TM; Lyons BC; Jackson K; Weiner JP; Saloner B
    Drug Alcohol Depend; 2019 Aug; 201():127-133. PubMed ID: 31207453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D.
    Strickland JC; Huhn AS; Bergeria CL; Strain EC; Dunn KE
    J Addict Med; 2021 Jul-Aug 01; 15(4):325-333. PubMed ID: 33156180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
    Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
    Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.
    Stein BD; Saloner B; Kerber R; Sorbero M; Gordon AJ
    Ann Emerg Med; 2022 May; 79(5):441-450. PubMed ID: 35305851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of naloxone access and primary medication nonadherence in a community pharmacy setting.
    Connolly E; McCall KL; Couture S; Felton M; Piper BJ; Bratberg JP; Tu C
    J Am Pharm Assoc (2003); 2022; 62(1):49-54. PubMed ID: 34736865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.